CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) · Gastric/GEJ · Biliary Tract Cancer (BTC) · Esophageal Squamous Cell Carcinoma (ESCC) · Ovarian Cancer · Endometrial Cancer · Cervical Cancer Metastatic · Non-small Cell Lung Cancer (NSCLC)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 219 (planned)
- Started
- Oct 21, 2026
- Main results expected
- Oct 2028
- Fully finished
- Jan 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Dose Escalation - incidence and nature of dose-limiting toxicities
Measured over: From the first dose of study drug up until approximately 1 month
Part 1: Dose Escalation - characterization of the maximum tolerated dose, if applicable
Measured over: From the first dose of study drug up until approximately 1 month
All Parts - incidence, nature, and severity of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events
Measured over: From the first dose of study drug until 90 days after the last dose of study drug
All Parts - incidence and severity of TEAEs leading to dose modifications
Measured over: From the first dose of study drug until 90 days after the last dose of study drug
All Parts - incidence and severity of TEAEs leading to treatment discontinuation
Measured over: From the first dose of study drug until 90 days after the last dose of study drug
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07909031 · record last updated 2026-11-02 · checked 2026-11-09 15:47 UTC